Biotech firm Electra Therapeutics has set a valuation target of nearly $1 billion for its upcoming initial public offering in the United States, signaling strong investor confidence in its potential. The company, which focuses on developing innovative cancer therapies, aims to raise capital through one of the most anticipated IPOs in the biotech sector this year. With growing demand for advanced treatment options, the offering could attract significant attention from both institutional and retail investors. Details on the exact offering size and pricing remain pending, but the high valuation underscores the sector’s optimism about next-generation oncology solutions.
Electra Therapeutics targets $977.6 million valuation in US IPO Reuters
